Skip to content
Triangle logo TriangleGet started
← Full study record

NCT06303167 · FLOW

Participant flow

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) · Source last updated 2026-05-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive osimertinib (AZD9291) 80 mg PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO or MUGA during screening, and biopsy and collection of blood samples on trial and at end of treatment.
    id
    FG000
    title
    Treatment (Osimertinib)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Ineligible
    2. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Never start protocol therapy
    3. reasons
      1. group Id
        FG000
        num Subjects
        16
      type
      Disease progression
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        19
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        17
      type
      Started Protocol Therapy
    3. achievements
      1. group Id
        FG000
        num Subjects
        16
      type
      Eligible and Treated
    4. achievements
      1. group Id
        FG000
        num Subjects
        13
      comment
      Primary efficacy analysis set
      type
      Eligible, Treated and Mutation Status Confirmed
    5. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    6. achievements
      1. group Id
        FG000
        num Subjects
        19
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Patients with an EGFR T790M mutation in any histology except lung cancer and patients with a rare activating mutation (EGFR G719A, G719C, G719D, G719S, L861Q, S786I, or an exon 19 in frame insertion mutations) in any histology were offered participation in this subprotocol. The mutation status was determined by a CLIA-approved assay performed in an NCI-MATCH approved laboratory for 16 patients in this arm, these cases had to be confirmed to be used in primary analysis.
recruitment Details
Subprotocol E was activated on August 12, 2015. Nineteen patients were enrolled between January 2016 and November 2021. Three patients were enrolled on the basis of the results from the NCI-MATCH assay and 16 on the basis of the outside assay results.
Complete source fields
groups
  1. description
    Patients receive osimertinib (AZD9291) 80 mg PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO or MUGA during screening, and biopsy and collection of blood samples on trial and at end of treatment.
    id
    FG000
    title
    Treatment (Osimertinib)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Ineligible
    2. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Never start protocol therapy
    3. reasons
      1. group Id
        FG000
        num Subjects
        16
      type
      Disease progression
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        19
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        17
      type
      Started Protocol Therapy
    3. achievements
      1. group Id
        FG000
        num Subjects
        16
      type
      Eligible and Treated
    4. achievements
      1. group Id
        FG000
        num Subjects
        13
      comment
      Primary efficacy analysis set
      type
      Eligible, Treated and Mutation Status Confirmed
    5. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    6. achievements
      1. group Id
        FG000
        num Subjects
        19
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Patients with an EGFR T790M mutation in any histology except lung cancer and patients with a rare activating mutation (EGFR G719A, G719C, G719D, G719S, L861Q, S786I, or an exon 19 in frame insertion mutations) in any histology were offered participation in this subprotocol. The mutation status was determined by a CLIA-approved assay performed in an NCI-MATCH approved laboratory for 16 patients in this arm, these cases had to be confirmed to be used in primary analysis.
recruitment Details
Subprotocol E was activated on August 12, 2015. Nineteen patients were enrolled between January 2016 and November 2021. Three patients were enrolled on the basis of the results from the NCI-MATCH assay and 16 on the basis of the outside assay results.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice